Eli Lilly's Obesity Drugs Show Promising Results for Weight Loss and FDA Approval.
TL;DR Summary
Eli Lilly has released new data to support its aim of fast-track FDA approval for tirzepatide, a drug for chronic weight management in people who have obesity or are overweight with weight-related conditions, but don't have diabetes. The drug has shown weight loss of up to 15.7% among people with Type 2 diabetes and obesity. The potential approval could come by the end of this year. However, access to the medication is a big challenge due to its high cost, and there are concerns about supply issues and side effects.
- Eli Lilly releases more data for new obesity drug, moving toward fast-track approval NPR
- New obesity drug Mounjaro poised to surpass Ozempic, Wegovy The Associated Press
- People with diabetes lost up to 34 pounds taking Eli Lilly drug, company says NBC News
- Blood sugar drug tirzepatide also leads to substantial weight loss in diabetes patients, Eli Lilly says CNN
- Eli Lilly's tirzepatide passes 2nd weight loss trial with flying colors, gunning for FDA nod in 2023 FiercePharma
Reading Insights
Total Reads
0
Unique Readers
10
Time Saved
4 min
vs 5 min read
Condensed
90%
897 → 90 words
Want the full story? Read the original article
Read on NPR